Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective
- DOI
- 10.1007/s41669-026-00674-7
- Published
- 2026-10-02
- Container
- PharmacoEconomics - Open
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s41669-026-00674-7,
title = {Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective},
author = {Dina Soliman and Christine Brezden-Masley and Sandeep Sehdev and Khalid El Ouagari and Natalia Sabater Anaya and Daniel Stellato and Talitha Vincken},
year = {2026},
journal = {PharmacoEconomics - Open},
doi = {10.1007/s41669-026-00674-7},
url = {https://doi.org/10.1007/s41669-026-00674-7}
}RIS
TY - JOUR TI - Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective AU - Dina Soliman AU - Christine Brezden-Masley AU - Sandeep Sehdev AU - Khalid El Ouagari AU - Natalia Sabater Anaya AU - Daniel Stellato AU - Talitha Vincken PY - 2026 JO - PharmacoEconomics - Open DO - 10.1007/s41669-026-00674-7 UR - https://doi.org/10.1007/s41669-026-00674-7 ER -
APA
Soliman, D., Brezden-Masley, C., Sehdev, S., Ouagari, K. E., Anaya, N. S., Stellato, D., & Vincken, T. (2026). Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-026-00674-7
Source records
- crossref · retrieved 2026-11-10T11:32:13.293Z